- Home
- HBCP vs CTNM Comparison
HBCP vs CTNM Comparison
Compare HBCP & CTNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Company Overview
Basic Information| Metric | HBCP | CTNM |
|---|---|---|
| Founded | 1908 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Banks | |
| Sector | Finance | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 495.8M | 507.0M |
| IPO Year | 2008 | 2024 |
Fundamental Metrics
Financial Performance| Metric | HBCP | CTNM |
|---|---|---|
| Price | $59.23 | $13.86 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 2 | 5 |
| Target Price | ★ $63.50 | $19.80 |
| AVG Volume (30 Days) | 55.3K | ★ 174.4K |
| Earning Date | 04-27-2026 | 06-08-2026 |
| Dividend Yield | ★ 2.13% | N/A |
| EPS Growth | ★ 29.01 | 0.46 |
| EPS | ★ 5.87 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $4.74 | N/A |
| P/E Ratio | $9.90 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $40.10 | $3.35 |
| 52 Week High | $64.17 | $16.33 |
Technical Indicators
Market Signals| Indicator | HBCP | CTNM |
|---|---|---|
| Relative Strength Index (RSI) | 44.67 | 45.22 |
| Support Level | $56.90 | $10.17 |
| Resistance Level | $61.18 | $16.17 |
| Average True Range (ATR) | 2.05 | 1.06 |
| MACD | -0.26 | -0.25 |
| Stochastic Oscillator | 38.81 | 16.25 |
Price Performance
Historical ComparisonAbout HBCP Home Bancorp Inc.
Home Bancorp Inc is engaged in attracting deposits from the public and using those funds to invest in loans and securities. The principal sources of funds are customer deposits, repayments of loans, repayments of investments and funds borrowed from outside sources such as the Federal Home Loan Bank of Dallas. These funds are used for the origination of loans, including one-to-four-family first mortgage loans, home equity loans, and lines, commercial real estate loans, construction and land loans, multi-family residential loans, commercial and industrial loans, and consumer loans.
About CTNM Contineum Therapeutics Inc.
Contineum Therapeutics Inc is a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies for NI&I indications with high unmet need. Its internally-discovered drug candidates, PIPE-791 and PIPE-307, PIPE-791, is a novel, brain penetrant, small molecule inhibitor of the LPA1R in development for IPF and PIPE-307, is a novel, small molecule selective inhibitor of the muscarinic type 1 M1R, in development for depression and RRMS.